Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. It also provides QUINSAIR, a formulation of the antibiotic drug levofloxacin for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients in Canada and Europe. The company s clinical development programs include RP103 that is used as a treatment for Huntington's disease; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. Its preclinical product candidates include RP105 and RP106 for various rare diseases. Raptor Pharmaceuticals Corp. has a license agreement with University of California. The company was founded in 2005 and is headquartered in Novato, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for RPTP